EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Mitigating Drug–Target–Drug Complexes in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Switch C5 Inhibitors

Jun-Ichi Nishimura, Antoine Soubret iD, Noriko Arase, Simon Buatois, Masaki Hotta, Jean-Eric Charoin, Yoshikazu Ito, Sasha Sreckovic, Hiroyuki Takamori, Christoph Bucher iD, Yasutaka Ueda, Jules Hernández-Sánchez und 17 weitere

Clinical Pharmacology & Therapeutics · 2023

DOI: 10.1002/cpt.2851 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2023. Verfasst von Jun-Ichi Nishimura und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Graduate School of Medicine, Faculty of Medicine, Osaka University, Osaka, Japan. Hauptthemen laut MEDLINE: Hemoglobinuria, Paroxysmal. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drug – target – drug complexes (DTDCs) are phenomena newly observed in patients who switch from the complement component 5 (C5) inhibitor eculizumab to crovalimab, a novel, anti‐C5 antibody in development for paroxysmal nocturnal hemoglobinuria (PNH), because these agents bind to different C5 epitopes. In Part 3 of the four‐part, phase I/II COMPOSER study, 19 patients with PNH switching from eculizumab received 1,000‐mg crovalimab intravenously, then subcutaneous maintenance doses from Day 8 (680 mg every 4 weeks (q4w), 340 mg every 2 weeks, or 170 mg every week). Crovalimab exposure was transiently reduced, and size‐exclusion chromatography and crovalimab‐specific enzyme‐linked immunosorbent assays revealed DTDCs in all 19 patients' sera. Additionally, self‐limiting mild to moderate symptoms suggestive of type III hypersensitivity reactions occurred in two patients. Mathematical modeling simulations of DTDC kinetics and effects of dosing on DTDC size distribution using Part 3 data predicted that increased crovalimab concentrations could reduce the proportion of large, slow‐clearing DTDCs in the blood. A simulation‐guided, optimized crovalimab regimen (1,000 mg intravenously; four weekly, subcutaneous 340‐mg doses; then 680 mg q4w from Day 29) was evaluated in Part 4. Confirming the model's predictions, mean proportions of large DTDCs in patients who switched from eculizumab to this optimized regimen decreased by > 50% by Day 22, and target crovalimab concentrations were maintained. No type III hypersensitivity reactions occurred in Part 4. Optimizing crovalimab dosing thus reduced the proportion of large DTDCs, ensured adequate complement inhibition, and may improve safety. Model‐based dosing optimization to mitigate DTDC formation offers a useful strategy for patients switching to novel antibody treatments targeting soluble epitopes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemoglobinuria, ParoxysmalHumansAntibodies, MonoclonalComplement Inactivating AgentsComplement C5

Substanzen

Antibodies, MonoclonalComplement Inactivating AgentsComplement C5

Autor:innen und Institutionen

  • Department of Hematology and Oncology, Graduate School of Medicine, Faculty of Medicine, Osaka University, Osaka, Japan.
  • Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
  • Department of Dermatology, Graduate School of Medicine, Faculty of Medicine, Osaka University, Osaka, Japan.
  • Department of Medical Technology, Osaka University Hospital, Osaka, Japan.
  • Department of Hematology, Tokyo Medical University Hospital, Tokyo, Japan.
  • Genentech, Inc., South San Francisco, California, USA.

ORCID-Profile: Antoine Soubret, Christoph Bucher, Yoshitaka Isaka

Zitieren

APA

Nishimura, J. I., Soubret, A., Arase, N., Buatois, S., Hotta, M., Charoin, J. E., Ito, Y., Sreckovic, S., Takamori, H., Bucher, C., Ueda, Y., Hernández-Sánchez, J., Gotanda, K., Jordan, G., Shinomiya, K., Ramos, J., Kim, J. S., Panse, J., de Latour, R. P., …, & Sostelly, A. (2023). Mitigating Drug–Target–Drug Complexes in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Switch C5 Inhibitors. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.2851

Vancouver

Nishimura JI, Soubret A, Arase N, Buatois S, Hotta M, Charoin JE, et al. Mitigating Drug–Target–Drug Complexes in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Switch C5 Inhibitors. Clinical Pharmacology & Therapeutics. 2023. doi:10.1002/cpt.2851

BibTeX
@article{Nishimura2023,
  author = {Nishimura, Jun-Ichi and Soubret, Antoine and Arase, Noriko and Buatois, Simon and Hotta, Masaki and Charoin, Jean-Eric and Ito, Yoshikazu and Sreckovic, Sasha and Takamori, Hiroyuki and Bucher, Christoph and Ueda, Yasutaka and Hernández-Sánchez, Jules and Gotanda, Keisuke and Jordan, Gregor and Shinomiya, Kenji and Ramos, Julia and Kim, Jin Seok and Panse, Jens and de Latour, Régis Peffault and Röth, Alexander and Morii, Eiichi and Schrezenmeier, Hubert and Isaka, Yoshitaka and Sica, Simona and Kanakura, Yuzuru and Yoon, Sung-Soo and Kinoshita, Taroh and Paz-Priel, Ido and Sostelly, Alexandre},
  title = {Mitigating Drug–Target–Drug Complexes in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Switch C5 Inhibitors},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2023},
  doi = {10.1002/cpt.2851}
}
Kostenlos starten →